Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1334

1.

P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).

Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Int J Pharm. 2019 Nov 20:118842. doi: 10.1016/j.ijpharm.2019.118842. [Epub ahead of print]

PMID:
31759109
2.

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, Bergman AM, van Erp NP, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Nov 15;36(12):181. doi: 10.1007/s11095-019-2706-4.

PMID:
31732882
3.

A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices.

Knikman JE, Rosing H, Guchelaar HJ, Cats A, Beijnen JH.

Biomed Chromatogr. 2019 Nov 6:e4732. doi: 10.1002/bmc.4732. [Epub ahead of print] Review.

PMID:
31691313
4.

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).

van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM.

Invest New Drugs. 2019 Oct 30. doi: 10.1007/s10637-019-00856-7. [Epub ahead of print]

PMID:
31667659
5.

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.

Jacobs BAW, Deenen MJ, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen JH, Schellens JHM, Huitema ADR.

CPT Pharmacometrics Syst Pharmacol. 2019 Oct 25. doi: 10.1002/psp4.12474. [Epub ahead of print]

6.

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).

van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.

Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]

PMID:
31637669
7.

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Crombag MBS, Koolen SLW, Wijngaard S, Joerger M, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Oct 15;36(12):163. doi: 10.1007/s11095-019-2697-1.

PMID:
31617004
8.

Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.

van Nuland M, Groenland SL, Bergman AM, Steeghs N, Rosing H, Venekamp N, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Oct 14. doi: 10.1038/s41391-019-0179-5. [Epub ahead of print]

PMID:
31611636
9.

Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer.

Roosendaal J, Rosing H, Lucas L, Gebretensae A, Huitema ADR, van Dongen MG, Beijnen JH, Oganesian A.

Invest New Drugs. 2019 Oct 11. doi: 10.1007/s10637-019-00854-9. [Epub ahead of print]

PMID:
31605293
10.

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.

van Nuland M, Bergman AM, Rosing H, de Vries N, Huitema ADR, Beijnen JH.

Pharmacotherapy. 2019 Dec;39(12):1137-1145. doi: 10.1002/phar.2339. Epub 2019 Nov 5.

PMID:
31596947
11.

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.

Yu H, Janssen JM, Sawicki E, van Hasselt JGC, de Weger VA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR.

J Clin Pharmacol. 2019 Oct 9. doi: 10.1002/jcph.1532. [Epub ahead of print]

PMID:
31595980
12.

Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.

Rood JJM, van Haren MJ, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2020 Jan 5;177:112871. doi: 10.1016/j.jpba.2019.112871. Epub 2019 Sep 10.

PMID:
31539712
13.

Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab.

Pluim D, Ros W, Miedema IHC, Beijnen JH, Schellens JHM.

Cytometry A. 2019 Oct;95(10):1053-1065. doi: 10.1002/cyto.a.23873. Epub 2019 Aug 12.

PMID:
31407460
14.

Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.

Bruin MAC, Rosing H, Lucas L, Wang J, Huitema ADR, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121723. doi: 10.1016/j.jchromb.2019.121723. Epub 2019 Jul 18.

PMID:
31352204
15.

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.

Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.

Mol Pharm. 2019 Sep 3;16(9):3842-3852. doi: 10.1021/acs.molpharmaceut.9b00475. Epub 2019 Aug 5.

PMID:
31329454
16.

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR.

Clin Pharmacokinet. 2019 Jul 16. doi: 10.1007/s40262-019-00803-y. [Epub ahead of print]

PMID:
31313068
17.

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH.

Cancer Chemother Pharmacol. 2019 Sep;84(3):487-499. doi: 10.1007/s00280-019-03905-3. Epub 2019 Jul 15. Review.

18.

P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.

Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32568. [Epub ahead of print]

PMID:
31304590
19.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.

Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 10;174:561-566. doi: 10.1016/j.jpba.2019.06.034. Epub 2019 Jun 24.

PMID:
31255856
20.

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM.

Clin Genitourin Cancer. 2019 Oct;17(5):e893-e896. doi: 10.1016/j.clgc.2019.05.026. Epub 2019 May 30. No abstract available.

PMID:
31248829
21.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.

Clin Cancer Res. 2019 Sep 15;25(18):5466-5474. doi: 10.1158/1078-0432.CCR-17-2299. Epub 2019 Jun 19.

PMID:
31217201
22.

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.

van Nuland M, Rosing H, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2019 Jun 18:e4623. doi: 10.1002/bmc.4623. [Epub ahead of print] Review.

PMID:
31215049
23.

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

Braal CL, Beijnen JH, Koolen SLW, Oomen-de Hoop E, Steeghs N, Jager A, Huitema ADR, Mathijssen RHJ.

J Clin Oncol. 2019 Aug 1;37(22):1980-1981. doi: 10.1200/JCO.19.00418. Epub 2019 Jun 18. No abstract available.

PMID:
31211599
24.

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.

Martínez-Chávez A, Rosing H, Hillebrand M, Tibben M, Schinkel AH, Beijnen JH.

Anal Bioanal Chem. 2019 Aug;411(20):5331-5345. doi: 10.1007/s00216-019-01932-w. Epub 2019 Jun 17.

25.

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

Crombag MBS, Haanen JBAG, Baas P, Beijnen JH, Huitema ADR.

J Geriatr Oncol. 2019 Jun 14. pii: S1879-4068(19)30118-3. doi: 10.1016/j.jgo.2019.06.001. [Epub ahead of print] No abstract available.

PMID:
31208830
26.

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).

van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Pharmacol Res. 2019 Aug;146:104297. doi: 10.1016/j.phrs.2019.104297. Epub 2019 Jun 5.

PMID:
31175939
27.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N.

Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318. doi: 10.1007/s00228-019-02704-2. Epub 2019 Jun 7.

PMID:
31175385
28.

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Li W, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:78-82. doi: 10.1016/j.jchromb.2019.05.026. Epub 2019 May 27.

29.

Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study.

Arnamo AH, Huitema AD, Beijnen JH, Nuijen B.

J Oncol Pharm Pract. 2019 Jun 2:1078155219850297. doi: 10.1177/1078155219850297. [Epub ahead of print]

PMID:
31156055
30.

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.

van Bussel MTJ, Beijnen JH, Brandsma D.

BMC Cancer. 2019 May 30;19(1):519. doi: 10.1186/s12885-019-5741-y.

31.

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

Tibben MM, Huijberts S, Li W, Schinkel AH, Gebretensae A, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 5;173:169-175. doi: 10.1016/j.jpba.2019.05.037. Epub 2019 May 21.

PMID:
31146172
32.

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Palić S, Bhairosing P, Beijnen JH, Dorlo TPC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02507-18. doi: 10.1128/AAC.02507-18. Print 2019 Jul.

33.

Predictive Value of Microdose Pharmacokinetics.

van Nuland M, Rosing H, Huitema ADR, Beijnen JH.

Clin Pharmacokinet. 2019 Oct;58(10):1221-1236. doi: 10.1007/s40262-019-00769-x. Review.

PMID:
31030372
34.

LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.

van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Jun 5;170:161-168. doi: 10.1016/j.jpba.2019.03.043. Epub 2019 Mar 20.

PMID:
30925273
35.

Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Dogan-Topal B, Li W, Schinkel AH, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. doi: 10.1016/j.jchromb.2019.02.017. Epub 2019 Feb 16.

36.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH.

Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22.

37.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141. doi: 10.1016/j.jchromb.2019.01.011. Epub 2019 Jan 22.

PMID:
30754019
38.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR.

Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2.

PMID:
30734241
39.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.

Durmus S, van der Valk M, Teunissen SF, Song JY, Wagenaar E, Beijnen JH, Schinkel AH.

Arch Toxicol. 2019 Mar;93(3):775-790. doi: 10.1007/s00204-019-02394-w. Epub 2019 Jan 30.

PMID:
30701287
40.

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Eur J Pharm Biopharm. 2019 Mar;136:120-130. doi: 10.1016/j.ejpb.2019.01.016. Epub 2019 Jan 17.

PMID:
30660696
41.

Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.

van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 1;1106-1107:26-34. doi: 10.1016/j.jchromb.2019.01.001. Epub 2019 Jan 3.

42.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR.

Clin Genitourin Cancer. 2019 Apr;17(2):e383-e386. doi: 10.1016/j.clgc.2018.12.004. Epub 2018 Dec 19. No abstract available.

43.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
44.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM.

Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.

PMID:
30608567
45.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.

Int J Pharm. 2019 Feb 10;556:172-180. doi: 10.1016/j.ijpharm.2018.12.014. Epub 2018 Dec 12.

PMID:
30553002
46.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
47.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
48.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.

PMID:
30485432
49.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:167-172. doi: 10.1016/j.jchromb.2018.10.023. Epub 2018 Oct 30.

50.

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM.

J Pharm Biomed Anal. 2019 Feb 5;164:128-134. doi: 10.1016/j.jpba.2018.10.025. Epub 2018 Oct 17.

PMID:
30368118

Supplemental Content

Loading ...
Support Center